ゲノム検査市場：構成要素別、技術別、用途別、流通チャネル別、最終用途別-2025-2030年の世界予測

ゲノム検査市場は、2023年に175億7,000万米ドルと評価され、2024年には197億6,000万米ドルに達すると予測され、CAGR 13.21％で成長し、2030年には419億米ドルに達すると予測されています。

ジェノタイピングとシーケンシングの両方を含むゲノム検査は、現代のヘルスケア、研究、個別化医療における貴重なツールです。その範囲には、疾患に対する遺伝的素因の検出、治療方針の決定、薬剤開発の支援などが含まれます。ゲノム検査の必要性は、個人の遺伝的体質に基づいて治療を個別化し、病気の早期発見と予防医療を可能にし、患者の転帰とコスト効率を高める可能性があることにあります。アプリケーションは、臨床診断や製薬研究から農業や家系調査まで、さまざまな分野に及んでいます。エンドユーザーは、ヘルスケアプロバイダーや研究機関から、パーソナライズされた健康洞察を求める消費者まで多岐にわたる。

ゲノム検査市場は、技術の進歩、シーケンシングのコスト低下、個別化医療に対する需要の高まりによって急速に発展しています。主な成長要因としては、遺伝性疾患に対する一般市民の意識の高まり、政府の支援イニシアティブ、精密医療におけるアプリケーションの拡大などが挙げられます。ポータブルゲノムシーケンサーの開発、ゲノミクスにおけるAIと機械学習の統合、法医学やバイオインフォマティクスなどヘルスケア以外の分野でのゲノミクスの利用拡大がチャンスとなります。こうした機会を捉えるため、企業はユーザーフレンドリーで手ごろな価格の検査ソリューションと堅牢なデータ分析プラットフォームの開発に注力すべきです。

しかし、この市場は、データプライバシーに関する懸念、遺伝子データ利用に関する倫理的問題、地域間で標準化された規制の欠如といった制約に直面しています。課題には、プライバシーの心配や遺伝知識の潜在的な心理的影響による消費者導入の障壁などがあります。このようなハードルを減らすことに成功したことで、特にデータ保護措置の強化や、より明確な規制枠組みの開発において、イノベーションの余地が生まれました。

持続的な成長のために、企業はCRISPRのようなゲノム編集技術の革新を優先し、デジタルヘルス・ソリューションを強化するためにテクノロジー企業との提携を模索し、遺伝子検査の利点を解明し倫理的懸念に対処するための教育普及活動に投資すべきです。ゲノム検査市場は非常にダイナミックであり、テクノロジーの絶え間ない進歩と、より包括的で統合された健康ソリューションへの漸進的なシフトが特徴です。

市場力学：急速に進化するゲノム検査市場の主要市場インサイトを公開

ゲノム検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中で増加する遺伝性疾患とがんの有病率
  • 疾病の早期発見と予防の重視の高まり
  • 個別化医療に対する意識の高まり
• 市場抑制要因
  • ゲノミクス機器に関連する高コスト
• 市場機会
  • 遺伝子配列決定とデータ解析の技術的進歩
  • 研究活動を促進するための政府のイニシアティブと資金提供の増加
• 市場の課題
  • 遺伝子情報の解釈に伴う複雑さ

ポーターのファイブフォース：ゲノム検査市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ゲノム検査市場における外部からの影響の把握

外部マクロ環境要因は、ゲノム検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ゲノム検査市場における競合情勢の把握

ゲノム検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスゲノム検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ゲノム検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ゲノム検査市場における成功への道筋を描く

ゲノム検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で遺伝性疾患やがんの罹患率が増加
    • 病気の早期発見と予防の重要性が高まっている
    • 個別化医療への意識の高まり
  • 抑制要因
    • ゲノミクス機器に関連する高コスト
  • 機会
    • 遺伝子配列解析とデータ分析における技術的進歩
    • 調査活動を促進するための政府の取り組みと資金の増加
  • 課題
    • 遺伝情報の解釈に伴う複雑さ
• 市場セグメンテーション分析
  • コンポーネント：ハイスループットシーケンシングのための機器の継続的な進歩
  • 技術：正確かつ包括的なゲノム解析により次世代シーケンシングの好感度が高まっている
  • アプリケーション：先進的なゲノム検査への投資の増加
  • 最終用途：遺伝性疾患に関する調査のための診断研究室における高度なゲノムの重要性の高まり
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ゲノム検査市場：コンポーネント別

• 消耗品
• 装置
• ソフトウェアとサービス

第7章 ゲノム検査市場：技術別

• マイクロアレイ
• 次世代シーケンシング
• ターゲットシーケンシング
• 全ゲノム配列解析

第8章 ゲノム検査市場：用途別

• がん
  • 脳腫瘍
  • 乳がん
  • 大腸がん
  • 肺がん
  • 悪性黒色腫
  • 卵巣がん
  • 前立腺がん
• 非がん
  • 心血管疾患
  • 神経疾患
  • 腫瘍

第9章 ゲノム検査市場：流通チャネル別

• オフライン
• オンライン

第10章 ゲノム検査市場：最終用途別

• 診断検査室
• 病院・クリニック

第11章 南北アメリカのゲノム検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のゲノム検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのゲノム検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • コーンヘルス、10万人のゲノムプロジェクトに備える
  • イルミナ、固形腫瘍の包括的なゲノムプロファイリングを可能にする先進的な液体生検アッセイを発表
  • アポロがチェンナイにゲノム研究所を開設、さらに3カ所を開設予定2023
• 戦略分析と提言

企業一覧

• 10x Genomics
• 23andMe, Inc
• Abbott Laboratories
• Agilent Technologies, Inc.
• BGI Group
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Eurofins Scientific SE
• F. Hoffmann-La Roche, Ltd.
• Freenome Holdings, Inc.
• GeneDx, LLC
• Genomic Testing Cooperative
• Helix OpCo, LLC
• Illumina, Inc.
• Merck KGaA
• New England Biolabs, Inc.
• Novogene Co, Ltd.
• Oxford Nanopore Technologies PLC
• PerkinElmer Inc.
• QIAGEN N.V.
• Quest Diagnostics Incorporated
• Takara Bio Inc
• Thermo Fisher Scientific Inc.
• Ultima Genomics, Inc.
• VWR International, LLC

LIST OF FIGURES

• FIGURE 1. GENOME TESTING MARKET RESEARCH PROCESS
• FIGURE 2. GENOME TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GENOME TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GENOME TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GENOME TESTING MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GENOME TESTING MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GENOME TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GENOME TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL GENOME TESTING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL GENOME TESTING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES GENOME TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES GENOME TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. GENOME TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. GENOME TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GENOME TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GENOME TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GENOME TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GENOME TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GENOME TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GENOME TESTING MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GENOME TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GENOME TESTING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GENOME TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GENOME TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GENOME TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GENOME TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GENOME TESTING MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GENOME TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GENOME TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GENOME TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GENOME TESTING MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL GENOME TESTING MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL GENOME TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL GENOME TESTING MARKET SIZE, BY NON-CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL GENOME TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL GENOME TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL GENOME TESTING MARKET SIZE, BY TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL GENOME TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL GENOME TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL GENOME TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL GENOME TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 59. CANADA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 60. CANADA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. CANADA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. CANADA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 63. CANADA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 64. CANADA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. CANADA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES GENOME TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 96. CHINA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 97. CHINA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 98. CHINA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. CHINA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 100. CHINA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 101. CHINA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. CHINA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 103. INDIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 104. INDIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. INDIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. INDIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 107. INDIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 108. INDIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. INDIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 115. INDONESIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. INDONESIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 122. JAPAN GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. JAPAN GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 129. MALAYSIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. MALAYSIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 136. PHILIPPINES GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. PHILIPPINES GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 143. SINGAPORE GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. SINGAPORE GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 150. SOUTH KOREA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 151. SOUTH KOREA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 157. TAIWAN GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. TAIWAN GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 164. THAILAND GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. THAILAND GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 171. VIETNAM GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. VIETNAM GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 180. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 186. DENMARK GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. DENMARK GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 193. EGYPT GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. EGYPT GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 200. FINLAND GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 201. FINLAND GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 207. FRANCE GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 208. FRANCE GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 214. GERMANY GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 215. GERMANY GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 221. ISRAEL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 222. ISRAEL GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 223. ITALY GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 224. ITALY GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 225. ITALY GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 226. ITALY GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 227. ITALY GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 228. ITALY GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. ITALY GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 235. NETHERLANDS GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 236. NETHERLANDS GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 242. NIGERIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 243. NIGERIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 249. NORWAY GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 250. NORWAY GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 251. POLAND GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 252. POLAND GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 253. POLAND GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 254. POLAND GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 255. POLAND GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 256. POLAND GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 257. POLAND GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 258. QATAR GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 259. QATAR GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 260. QATAR GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 261. QATAR GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 262. QATAR GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 263. QATAR GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 264. QATAR GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 270. RUSSIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 271. RUSSIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 277. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 278. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 284. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 285. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 287. SPAIN GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 289. SPAIN GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 290. SPAIN GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 291. SPAIN GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 292. SPAIN GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 293. SWEDEN GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 294. SWEDEN GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 296. SWEDEN GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 297. SWEDEN GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 298. SWEDEN GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 299. SWEDEN GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 300. SWITZERLAND GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 301. SWITZERLAND GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 302. SWITZERLAND GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 303. SWITZERLAND GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 304. SWITZERLAND GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 305. SWITZERLAND GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 306. SWITZERLAND GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 307. TURKEY GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 308. TURKEY GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 309. TURKEY GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 310. TURKEY GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 311. TURKEY GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 312. TURKEY GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 313. TURKEY GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 314. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 315. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 316. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 317. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 318. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 319. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 320. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 321. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 322. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 323. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 324. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 325. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
• TABLE 326. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 327. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 328. GENOME TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 329. GENOME TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Genome Testing Market was valued at USD 17.57 billion in 2023, expected to reach USD 19.76 billion in 2024, and is projected to grow at a CAGR of 13.21%, to USD 41.90 billion by 2030.

Genome testing, encompassing both genotyping and sequencing, is an invaluable tool in modern healthcare, research, and personalized medicine. Its scope includes detecting genetic predispositions to diseases, guiding treatment decisions, and aiding in drug development. The necessity of genome testing is driven by its potential to personalize medical treatments based on an individual's genetic makeup, enabling early disease detection and preventative healthcare, which enhances patient outcomes and cost efficiency. Applications extend across various sectors, from clinical diagnostics and pharmaceutical research to agriculture and ancestry tracing. End users range from healthcare providers and research institutions to consumers seeking personalized health insights.

The market for genome testing is rapidly evolving, spurred by technological advancements, decreasing costs of sequencing, and increasing demand for personalized medicine. Key growth influencers include increased public awareness of genetic diseases, supportive government initiatives, and expanding applications in precision medicine. Opportunities arise from the development of portable genome sequencers, integration of AI and machine learning in genomics, and expanding the use of genomics in non-healthcare fields such as forensic sciences and bioinformatics. To seize these opportunities, companies should focus on developing user-friendly, affordable testing solutions and robust data analytics platforms.

However, the market faces limitations such as data privacy concerns, ethical issues regarding genetic data usage, and a lack of standardized regulations across regions. Challenges include barriers to consumer adoption due to privacy worries and potential psychological impacts of genetic knowledge. Achievements in reducing these hurdles present room for innovation, particularly in enhancing data protection measures and in developing clearer regulatory frameworks.

For sustained growth, businesses should prioritize innovation in genome editing technologies like CRISPR, explore partnerships with technology firms to enhance digital health solutions, and invest in the educational outreach to demystify genetic testing benefits and address ethical concerns. The genome testing market is highly dynamic, marked by continuous advancements in technology and a gradual shift towards more comprehensive and integrated health solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Genome Testing Market

The Genome Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of genetic disorders and cancer across the globe
  • Growing emphasis on early disease detection & prevention
  • Increasing awareness of personalized medicine
• Market Restraints
  • High cost associated with genomics equipment
• Market Opportunities
  • Technological advancements in gene sequencing and data analysis
  • Rising government initiatives and fundings for boosting research activities
• Market Challenges
  • Complexities associated with the interpreting genetic information

Porter's Five Forces: A Strategic Tool for Navigating the Genome Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Genome Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Genome Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Genome Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Genome Testing Market

A detailed market share analysis in the Genome Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Genome Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Genome Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Genome Testing Market

A strategic analysis of the Genome Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genome Testing Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, 23andMe, Inc, Abbott Laboratories, Agilent Technologies, Inc., BGI Group, Bio-Rad Laboratories, Inc., Danaher Corporation, Eurofins Scientific SE, F. Hoffmann-La Roche, Ltd., Freenome Holdings, Inc., GeneDx, LLC, Genomic Testing Cooperative, Helix OpCo, LLC, Illumina, Inc., Merck KGaA, New England Biolabs, Inc., Novogene Co, Ltd., Oxford Nanopore Technologies PLC, PerkinElmer Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Takara Bio Inc, Thermo Fisher Scientific Inc., Ultima Genomics, Inc., and VWR International, LLC.

Market Segmentation & Coverage

This research report categorizes the Genome Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Component, market is studied across Consumables, Equipment, and Software & Services.
• Based on Technology, market is studied across Microarrays, Next-Generation Sequencing, Targeted Sequencing, and Whole Genome Sequencing.
• Based on Application, market is studied across Cancer and Non-cancer. The Cancer is further studied across Brain Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, and Prostate Cancer. The Non-cancer is further studied across Cardiovascular Diseases, Neurological Disorders, and Tumors.
• Based on Distribution Channel, market is studied across Offline and Online.
• Based on End-use, market is studied across Diagnostic Laboratories and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of genetic disorders and cancer across the globe
    • 5.1.1.2. Growing emphasis on early disease detection & prevention
    • 5.1.1.3. Increasing awareness of personalized medicine
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with genomics equipment
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in gene sequencing and data analysis
    • 5.1.3.2. Rising government initiatives and fundings for boosting research activities
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities associated with the interpreting genetic information
• 5.2. Market Segmentation Analysis
  • 5.2.1. Component: Ongoing advancements in equipments for high-throughput sequencing
  • 5.2.2. Technology: Increasing preference of next-generation sequencing due to its precise and comprehensive genomic analysis
  • 5.2.3. Application: Increasing investment for advance genome testing across
  • 5.2.4. End-use: Rising significance of advanced genomic in diagnostic laboratories for research associated with genetic diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Genome Testing Market, by Component

• 6.1. Introduction
• 6.2. Consumables
• 6.3. Equipment
• 6.4. Software & Services

7. Genome Testing Market, by Technology

• 7.1. Introduction
• 7.2. Microarrays
• 7.3. Next-Generation Sequencing
• 7.4. Targeted Sequencing
• 7.5. Whole Genome Sequencing

8. Genome Testing Market, by Application

• 8.1. Introduction
• 8.2. Cancer
  • 8.2.1. Brain Cancer
  • 8.2.2. Breast Cancer
  • 8.2.3. Colorectal Cancer
  • 8.2.4. Lung Cancer
  • 8.2.5. Melanoma
  • 8.2.6. Ovarian Cancer
  • 8.2.7. Prostate Cancer
• 8.3. Non-cancer
  • 8.3.1. Cardiovascular Diseases
  • 8.3.2. Neurological Disorders
  • 8.3.3. Tumors

9. Genome Testing Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Offline
• 9.3. Online

10. Genome Testing Market, by End-use

• 10.1. Introduction
• 10.2. Diagnostic Laboratories
• 10.3. Hospitals & Clinics

11. Americas Genome Testing Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Genome Testing Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Genome Testing Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Cone Health Readies for 100,000 Person Genomics Project
  • 14.3.2. Illumina Launches Advanced Liquid Biopsy Assay to Enable Comprehensive Genomic Profiling of Solid Tumors
  • 14.3.3. Apollo Opens Genomic Institute In Chennai, to Open Three More in 2023
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 10x Genomics
• 2. 23andMe, Inc
• 3. Abbott Laboratories
• 4. Agilent Technologies, Inc.
• 5. BGI Group
• 6. Bio-Rad Laboratories, Inc.
• 7. Danaher Corporation
• 8. Eurofins Scientific SE
• 9. F. Hoffmann-La Roche, Ltd.
• 10. Freenome Holdings, Inc.
• 11. GeneDx, LLC
• 12. Genomic Testing Cooperative
• 13. Helix OpCo, LLC
• 14. Illumina, Inc.
• 15. Merck KGaA
• 16. New England Biolabs, Inc.
• 17. Novogene Co, Ltd.
• 18. Oxford Nanopore Technologies PLC
• 19. PerkinElmer Inc.
• 20. QIAGEN N.V.
• 21. Quest Diagnostics Incorporated
• 22. Takara Bio Inc
• 23. Thermo Fisher Scientific Inc.
• 24. Ultima Genomics, Inc.
• 25. VWR International, LLC